Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is a leading science and technology company delivering life-transforming medicine for serious diseases. The company’s blockbuster drug, Eylea, treats wet age-related macular degeneration (AMD). Recently, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has been exploring the use of the drug in other areas due to emerging medicines that threaten Eylea’s stronghold in the AMD arena.
The company rolled out interesting Phase 3 results for Eylea in non-proliferative diabetic retinopathy. Eylea injections improved diabetic retinopathy, reduced vision-threatening complications and cut the development of center-involved diabetic macular edema. These promising results are just one of the reasons Regeneron Pharmaceuticals Inc (NASDAQ: REGN) continues to climb the Top 100 stock investment grades on Hade Platform.
Why should you trust our ratings? The simple answer is our results speak for themselves. The Hade Platform has proven over the course of three years through the application of DLAs and artificial intelligence that it consistently outperforms Wall Street consensus estimates (63%) and major benchmarks such as the S&P 500 (250%). Access our premium services and start beating the market.
With overall investment grades still lower, we suggest holding large sums of cash and being very selective when making investment decisions. According to REGN stock’s current grade, it might very well be one of those selective opportunities.